hit counter
Affimed N.V. (AFMD) Stock News Sentiment & Price - Sentifly
AFMD - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



Affimed N.V. (AFMD)

Germany
Biotechnology
NASDAQ
AFMD Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AFMD Latest news
The Motley Fool
Positive
2 Biotech Stocks Set to Go Supernova Soon
2021-10-18 07:45

Anavex Life Sciences and Affimed both sport unique drug development platforms that could be worth billions.

Seeking Alpha
Positive
Affimed: Preparing For A Bullish 2022
2021-10-11 21:09

Affimed: Preparing For A Bullish 2022

GlobeNewsWire
Neutral
Affimed Announces Acceptance of Three Abstracts with Preclinical Data on Its Innate Cell Engagers at the 36th Annual Meeting of the Society for Immunotherapy of Cancer
2021-10-01 08:05

HEIDELBERG, Germany, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that three abstracts with preclinical data of its innate cell engagers have been accepted for poster presentation at the 36th Annual Meeting of the Society for Immunotherapy of Cancer (SITC), which will be held on November 10-14, 2021.

Zacks Investment Research
Negative
New Strong Sell Stocks for September 29th
2021-09-29 12:48

AFMD, FSLR, MU, BCE, and USNA have been added to the Zacks Rank #5 (Strong Sell) List on September 29, 2021.

Zacks Investment Research
Negative
New Strong Sell Stocks for September 13th
2021-09-13 11:10

AFMD, DZSI, GMBL, NTRB, and SURF have been added to the Zacks Rank #5 (Strong Sell) List on September 13, 2021.

Seeking Alpha
Neutral
Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2021 Results - Earnings Call Transcript
2021-09-08 14:24

Affimed N.V. (AFMD) CEO Adi Hoess on Q2 2021 Results - Earnings Call Transcript

Zacks Investment Research
Negative
Affimed N.V. (AFMD) Reports Q2 Loss, Lags Revenue Estimates
2021-09-08 10:15

Affimed N.V. (AFMD) delivered earnings and revenue surprises of -171.43% and -13.79%, respectively, for the quarter ended June 2021.

GlobeNewsWire
Neutral
Affimed Reports Second Quarter 2021 Financial Results and Highlights Operational Progress
2021-09-08 06:30

HEIDELBERG, Germany, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today reported financial results for the quarter ended June 30, 2021, and provided an update on clinical and corporate progress.

GlobeNewsWire
Neutral
Affimed to Present at Upcoming Investor Conferences
2021-08-26 06:30

HEIDELBERG, Germany, Aug. 26, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that management will present and host one-on-one meetings at the following investor conferences during the month of September 2021.

GlobeNewsWire
Neutral
Affimed to Report Second Quarter 2021 Financial Results & Corporate Update on September 8, 2021
2021-08-23 06:30

HEIDELBERG, Germany, Aug. 23, 2021 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, today announced that it will release second quarter 2021 results on Wednesday, September 8, 2021, and host a conference call at 8:30 a.m. EDT to discuss financial results and recent corporate developments.

Loading more news...